These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12445753)

  • 1. Phase II study of irinotecan and carboplatin for advanced non-small cell lung cancer.
    Takeda K; Takifuji N; Uejima H; Yoshimura N; Terakawa K; Negoro S
    Lung Cancer; 2002 Dec; 38(3):303-8. PubMed ID: 12445753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma.
    Okamoto H; Nagatomo A; Kunitoh H; Kunikane H; Watanabe K
    Cancer; 1998 Jun; 82(11):2166-72. PubMed ID: 9610696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dose-escalation study of irinotecan (CPT-11) in combination with cisplatin in patients with advanced non-small cell lung cancer previously treated with a docetaxel-based front line chemotherapy.
    Kakolyris S; Souglakos J; Agelaki S; Kourousis CH; Mavroudis D; Sarra E; Malliotakis P; Georgoulias V
    Lung Cancer; 2000 Dec; 30(3):193-8. PubMed ID: 11137204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose escalation study of irinotecan combined with carboplatin for advanced non-small-cell lung cancer.
    Takeda K; Negoro S; Takifuji N; Nitta T; Yoshimura N; Terakawa K; Fukuoka M
    Cancer Chemother Pharmacol; 2001 Aug; 48(2):104-8. PubMed ID: 11561775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Weekly chemotherapy with carboplatin, docetaxel and irinotecan in advanced non-small-cell-lung cancer: a phase II study.
    Pectasides D; Visvikis A; Kouloubinis A; Glotsos J; Bountouroglou N; Karvounis N; Ziras N; Athanassiou A
    Eur J Cancer; 2002 Jun; 38(9):1194-200. PubMed ID: 12044505
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of weekly carboplatin and irinotecan as first-line chemotherapy for patients with advanced non-small cell lung cancer.
    Kim HS; Kim JH; Kim B; Choi HC; Kwon JH; Choi DR
    Cancer Chemother Pharmacol; 2013 Jun; 71(6):1591-7. PubMed ID: 23568282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II trial of irinotecan, paclitaxel and carboplatin in patients with previously untreated Stage IIIB/IV nonsmall cell lung carcinoma.
    Socinski MA; Sandler AB; Israel VK; Gillenwater HH; Miller LL; Locker PK; Antonellini A; Elfring GL; Natale RB
    Cancer; 2002 Oct; 95(7):1520-7. PubMed ID: 12237921
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I trial of the combination of irinotecan, paclitaxel, and carboplatin in patients with advanced non-small-cell lung cancer.
    Socinski MA; Sandler AB; Miller LL; Locker PK; Hanover CK; Elfring GL; Israel VK; Pirotta N; Natale RB
    J Clin Oncol; 2001 Feb; 19(4):1078-87. PubMed ID: 11181672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of irinotecan combined with carboplatin in previously untreated non-small-cell lung cancer.
    Fukuda M; Oka M; Soda H; Kinoshita A; Fukuda M; Nagashima S; Kuba M; Takatani H; Tsurutani J; Nakamura Y; Kasai T; Inoue Y; Soejima Y; Kohno S;
    Cancer Chemother Pharmacol; 2004 Dec; 54(6):573-7. PubMed ID: 15365766
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A phase I-II study of bi-weekly gemcitabine and irinotecan as second-line chemotherapy in non-small cell lung cancer after prior taxane + platinum-based regimens.
    Kosmas C; Tsavaris N; Syrigos K; Koutras A; Tsakonas G; Makatsoris T; Mylonakis N; Karabelis A; Stathopoulos GP; Kalofonos HP
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):51-9. PubMed ID: 16622691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Weekly irinotecan and cisplatin in advanced non-small cell lung cancer: a multicenter phase II study.
    Jagasia MH; Langer CJ; Johnson DH; Yunus F; Rodgers JS; Schlabach LL; Cohen AG; Shyr Y; Carbone DP; Devore RF
    Clin Cancer Res; 2001 Jan; 7(1):68-73. PubMed ID: 11205920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I/II and pharmacologic study of irinotecan and carboplatin for patients with lung cancer.
    Sato M; Ando M; Minami H; Ando Y; Ando M; Yamamoto M; Sakai S; Watanabe A; Ikeda T; Sekido Y; Saka H; Shimokata K; Hasegawa Y
    Cancer Chemother Pharmacol; 2001 Dec; 48(6):481-7. PubMed ID: 11800029
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I study and pharmacokinetics of irinotecan (CPT-11) and paclitaxel in patients with advanced non-small cell lung cancer.
    Hotta K; Ueoka H; Kiura K; Tabata M; Kuyama S; Satoh K; Kozuki T; Hisamoto A; Hosokawa S; Fujiwara K; Tanimoto M
    Lung Cancer; 2004 Jul; 45(1):77-84. PubMed ID: 15196737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A dose-escalation study of irinotecan (CPT-11) in combination with gemcitabine in patients with advanced non-small cell lung cancer previously treated with a cisplatin-based front line chemotherapy.
    Kakolyris SS; Kouroussis C; Koukourakis M; Kalbakis K; Mavroudis D; Vardakis N; Georgoulias V
    Anticancer Res; 2002; 22(3):1891-6. PubMed ID: 12168889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I/II study of escalating doses of nedaplatin in combination with irinotecan for advanced non-small-cell lung cancer.
    Oshita F; Yamada K; Kato Y; Ikehara M; Noda K; Tanaka G; Nomura I; Suzuki R; Saito H
    Cancer Chemother Pharmacol; 2003 Jul; 52(1):73-8. PubMed ID: 12750839
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I study of weekly CPT-11 (irinotecan)/docetaxel in patients with advanced solid tumors.
    Font A; Sanchez JM; Rosell R; Taron M; Martinez E; Guillot M; Manzano JL; Margeli M; Barnadas A; Abad A
    Lung Cancer; 2002 Aug; 37(2):213-8. PubMed ID: 12140145
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of irinotecan and carboplatin in patients with the refractory or relapsed small cell lung cancer.
    Hirose T; Horichi N; Ohmori T; Ogura K; Hosaka T; Ando K; Ishida H; Noguchi H; Adachi M
    Lung Cancer; 2003 Jun; 40(3):333-8. PubMed ID: 12781433
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer. A phase II trial.
    Paccagnella A; Favaretto A; Oniga F; Festi G; Lauro S; Morabito A; Ossana L; Sartore F; DePoli F; Fiorentino MV
    Cancer; 1996 Oct; 78(8):1701-7. PubMed ID: 8859183
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of irinotecan (CPT-11) and carboplatin in patients with limited disease small cell lung cancer (SCLC).
    Laack E; Thöm I; Krüll A; Engel-Riedel W; Müller T; Meissner C; Dürk H; Fischer J; Gütz S; Kortsik C; Elbers M; Schuch G; Andritzky B; Görn M; Burkholder I; Edler L; Hossfeld DK; Bokemeyer C
    Lung Cancer; 2007 Aug; 57(2):181-6. PubMed ID: 17442447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Salvage treatment of advanced non-small-cell lung cancer previously treated with docetaxel-based front-line chemotherapy with irinotecan (CPT-11) in combination with cisplatin.
    Kakolyris S; Kouroussis C; Kalbakis K; Mavroudis D; Souglakos J; Nvardakis ; Kremos S; Georgoulias V
    Ann Oncol; 2000 Jun; 11(6):757-60. PubMed ID: 10942068
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.